Active Targeted Macrophage-mediated Delivery of Catalase to Affected Brain Regions in Models of Parkinson's Disease
- *Corresponding Author:
- Dr. Elena V. Batrakova
Center for Drug Delivery and Nanomedicine
985830 Nebraska Medical Center
Omaha, NE 68198-5830
Tel: (402) 559-9364
Fax: (402) 559-9365
Email: [email protected]
Received Date: July 30, 2011; Accepted Date: September 07, 2011; Published Date: September 10, 2011
Citation: Zhao Y, Haney MJ, Mahajan V, Reiner BC, Dunaevsky A, et al. (2011) Active Targeted Macrophage-mediated Delivery of Catalase to Affected Brain Regions in Models of Parkinson’s Disease. J Nanomedic Nanotechnol S4:003. doi:10.4172/2157-7439.S4-003
Copyright: © 2011 Zhao Y, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
We previously demonstrated that monocyte-macrophage based drug delivery can be applied to a spectrum of infectious, neoplastic, and degenerative disorders. In particular, bone marrow-derived macrophages (BMM) loaded with nano formulated catalase, “ nanozyme”, were shown to attenuate neuro inflammation and nigrostriatal degeneration in rodent models of Parkinson’s disease (PD). Nonetheless, the pharmacokinetics and biodistribution of BMM- incorporated nanozyme has not been explored. To this end, we now demonstrate that BMM, serving as a “depot” for nanozyme, increased area under the curve(AUC), half-life, and mean residence time in blood circulation of the protein when compared to the nanozyme administered alone. Accordingly, bioavailability of the nanozyme for the brain, spleen, kidney, and liver was substantially increased. Importantly, nanozyme-loaded BMM targeted diseased sites and improved transport across the blood brain barrier. This was seen specifically in affected brain subregions in models of PD. Engaging natural immune cells such as monocyte-macrophages as drug carriers provides a new perspective for therapeutic delivery for PD and also likely a range of other inflammatory and degenerative diseases.